COMPANY

Sellas Life Sciences Group

HQ: New York, NY source · sellaslifesciences.com ↗

Keywords: oncology cancer Acute Myeloid Leukemia Hematologic Malignancies Myelodysplastic Syndromes Acute Lymphoblastic Leukemia Acute Myelogenous Leukemia Ovarian Cancer Colorectal Cancer Triple-negative Breast Cancer Small-cell Lung Cancer Malignant Pleural Mesothelioma Multiple Myeloma SLS009 Galinpepimut-S

Location: New York, NY · source · Oct 12, 2026

Profile checked Oct 10, 2026

7Trials (company is sponsor)

Timeline

May 10, 2021 Trial start Phase 1/Phase 2: Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML source ↗
Feb 8, 2021 Trial start Phase 3: Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 source ↗
Sep 30, 2019 Trial start Phase 1/Phase 2: Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers source ↗
2013-04 Trial start Phase 1/Phase 2: WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation source ↗
Jan 14, 2011 Trial start Phase 2: WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) source ↗
Dec 21, 2010 Trial start Phase 2: Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy source ↗

Upcoming milestones

Dec 30, 2026 (ESTIMATED) · Phase 1/Phase 2 · Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML · NCT04588922

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 7

Record	Title	Phase	Status	Start	Primary completion
NCT04588922	Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML	Phase 1/Phase 2	Recruiting	May 10, 2021	Dec 30, 2026 (estimated)
NCT05593185	Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS	Not listed	Available	Not listed	Not listed
NCT04229979	Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2	Phase 3	Active, not recruiting	Feb 8, 2021	2025-12 (estimated)
NCT01266083	WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)	Phase 2	Completed	Jan 14, 2011	Sep 30, 2016 (actual)
NCT03761914	Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers	Phase 1/Phase 2	Completed	Sep 30, 2019	Jul 5, 2022 (actual)
NCT01265433	Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy	Phase 2	Completed	Dec 21, 2010	Nov 30, 2016 (actual)
NCT01827137	WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation	Phase 1/Phase 2	Completed	2013-04	Dec 7, 2016 (actual)